STOCK TITAN

Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Vir Biotechnology, Inc. (VIR) will be participating in key investor conferences in March, with Marianne De Backer, CEO, engaging in fireside chats and one-on-one meetings. The events aim to enhance investor relations and showcase the company's progress.
Positive
  • None.
Negative
  • None.

SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that management will be participating in the following upcoming investor conferences during the month of March:

  • TD Cowen 44th Annual Health Care Conference at the Boston Marriott Copley Place in Boston. Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, is scheduled to participate in a fireside chat on Monday, March 4, at 2:50 p.m. ET / 11:50 a.m. PT.
  • Leerink Partners Global Biopharma Conference at the Fontainebleau Hotel in Miami Beach. Vir management will be hosting one-on-one investor meetings on Monday, March 11 and Tuesday, March 12.
  • Barclays 26th Annual Global Healthcare Conference at Loews Miami Beach Hotel in Miami. Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, is scheduled to participate in a fireside chat on Tuesday, March 12, at 7:30 a.m. ET / 4:30 a.m. PT.

Live webcasts of the fireside chats can be accessed under Events & Presentations in the Investors section of the Vir website at www.vir.bio and will be archived there for 30 days.

About Vir Biotechnology, Inc.

Vir Biotechnology, Inc. is an immunology company focused on powering the immune system to transform lives by treating and preventing infectious diseases and other serious conditions, including viral-associated diseases. Vir has assembled two technology platforms that are designed to modulate the immune system by exploiting critical observations of natural immune processes. Its current clinical development pipeline consists of product candidates targeting hepatitis delta and hepatitis B viruses and human immunodeficiency virus. Vir has several preclinical candidates in its pipeline, including those targeting influenza A and B, COVID-19, RSV/MPV and HPV. Vir routinely posts information that may be important to investors on its website.

Carly Scaduto

Senior Director, Media Relations

cscaduto@vir.bio

+1-314-368-5189

Investors

Richard Lepke

Senior Director, Investor Relations

rlepke@vir.bio

+1 978-973-9986

Source: Vir Biotechnology, Inc.

Marianne De Backer is scheduled to participate in a fireside chat on Monday, March 4, at 2:50 p.m. ET / 11:50 a.m. PT.

Vir management will be hosting one-on-one investor meetings at the Fontainebleau Hotel in Miami Beach on Monday, March 11 and Tuesday, March 12.

The live webcasts of the fireside chats can be accessed on the Vir website at www.vir.bio under Events & Presentations and will be archived for 30 days.
Vir Biotechnology Inc

NASDAQ:VIR

VIR Rankings

VIR Latest News

VIR Stock Data

Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
Commercial Services, Miscellaneous Commercial Services, Health Technology, Biotechnology

About VIR

vir brings together cutting-edge innovations with leading scientific expertise and management to take on some of the world’s most challenging infectious diseases for which solutions are non-existent or inadequate. vir seeks to take a new approach, using breakthroughs in immune programming to manipulate pathogen-host interactions. the company will take a multi-program, multi-platform approach to applying these breakthroughs, guided by rigorous science and driven by medical need.